Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Shares Outstanding (Diluted Average): 2014-2025

Historic Shares Outstanding (Diluted Average) for Altimmune (ALT) over the last 7 years, with Sep 2025 value amounting to $89.4 million.

  • Altimmune's Shares Outstanding (Diluted Average) rose 25.79% to $89.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.4 million, marking a year-over-year increase of 25.79%. This contributed to the annual value of $71.0 million for FY2024, which is 33.35% up from last year.
  • Latest data reveals that Altimmune reported Shares Outstanding (Diluted Average) of $89.4 million as of Q3 2025, which was up 9.75% from $81.5 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Shares Outstanding (Diluted Average) ranged from a high of $89.4 million in Q3 2025 and a low of $38.9 million during Q1 2021.
  • In the last 3 years, Altimmune's Shares Outstanding (Diluted Average) had a median value of $70.9 million in 2024 and averaged $67.1 million.
  • Data for Altimmune's Shares Outstanding (Diluted Average) shows a peak YoY surged of 61.03% (in 2021) over the last 5 years.
  • Altimmune's Shares Outstanding (Diluted Average) (Quarterly) stood at $41.3 million in 2021, then rose by 13.67% to $46.9 million in 2022, then rose by 13.47% to $53.2 million in 2023, then surged by 33.35% to $71.0 million in 2024, then climbed by 25.79% to $89.4 million in 2025.
  • Its last three reported values are $89.4 million in Q3 2025, $81.5 million for Q2 2025, and $75.5 million during Q1 2025.